Arbeitsgemeinschaft medikamentöse Tumortherapie

What Arbeitsgemeinschaft medikamentöse Tumortherapie does

Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT) is an Austrian non-profit academic clinical research organization (gemeinnützige GmbH) headquartered in Vienna (Gentzgasse 60/21, 1180 Wien) with a branch office in Salzburg (Wolfsgartenweg 31, 5020 Salzburg). The organization brings together scientifically active clinicians and researchers in oncology, hematology, and adjacent disciplines to design, sponsor, and coordinate multicenter clinical trials with the stated mission of improving treatment outcomes for patients with malignant tumor diseases, advancing modern therapy approaches, and promoting clinical and scientific education in Austria. AGMT serves oncology/hematology patients, clinical investigators at Austrian university hospitals, and international academic study groups plus pharmaceutical sponsors that retain AGMT as their Austrian national sponsor representative.

AGMT's core offerings span three product categories. First, a portfolio of more than 30 active or completed clinical trials including Phase I/II investigator-initiated studies (e.g., MBC-10/CARIXA in triple-negative breast cancer) and Phase III registration-supporting trials in Hodgkin lymphoma (HD21, BRESELIBET), non-Hodgkin lymphoma (DSHNHL_NIVEAU, Pola-R-ICE, R-Pola-Glo, MorningLyte), multiple myeloma (MM-4, DSMM XVII, GMMG-HD8/DSMM XIX, GMMG-HD9/DSMM XVIII), colorectal cancer (SAKK 41/14 Active-2), pancreatic cancer (DIsCOvER), and COVID-19 (INSERM_DisCoVeRy). Second, a registry platform of at least nine disease registries (aMYELOIDr, ARIADNE NIS, CLL-Register, EMCL-Registry, LungCA, MBC, mCRC-3L, NGS Register, plus a COVID-19 Register) capturing Austrian real-world treatment data and the implementation speed of scientific findings. Third, recurring scientific events including the AGMT Jahresmeeting (next edition November 13–14, 2026 at Hotel Gersbergalm) and the Salzburg Breast Cancer Talk immuno-oncology conference series (5th edition March 2024). Underlying technical components are process- rather than product-based: pseudonymized clinical data processing with code-key separation maintained exclusively at trial sites, CTR / Austrian Medicines Act / GDPR compliance, and ISO certification via Quality Austria.

AGMT operates as a grant- and contract-funded professional services organization with no publicly disclosed pricing. Revenue is derived from clinical trial coordination fees, regulatory and sponsor-representative services, and grant funding from pharmaceutical industry partners, public research institutions, and international academic study groups including GHSG, GELTAMO, DSMM, GMMG, SAKK, INSERM, LYSARC, GWT-TUD, and IKF. The go-to-market motion is event- and network-driven: principal-investigator relationships at Austrian university hospitals (notably University Hospital Salzburg / Paracelsus Medical University, anchored by Prof. Richard Greil), peer-reviewed publications in high-impact journals (Lancet, Lancet Oncology, JCO, Blood), scientific congress presentations, and the AGMT Jahresmeeting and Salzburg Breast Cancer Talk conference series constitute the primary channels for trial investigator recruitment and sponsor acquisition.

Name

Arbeitsgemeinschaft medikamentöse Tumortherapie

Legal name

Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH

Website

https://agmt.at

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

AGMT is an Austrian non-profit academic clinical research organization that conducts Phase I–III oncology and hematology trials as the Austrian sponsor representative for international study groups (GHSG, DSMM/GMMG, SAKK, INSERM, LYSARC), operates nine disease registries capturing real-world treatment data, and serves patients, investigators, and pharmaceutical sponsors across Austria and Europe.

Ownership category

akta.pro rank

Product category

Clinical Research Organization Services (Oncology/Hematology)

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro industry

PRIMARYHLAGAAAL

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGACAE

Clinical Trial Site Operations & Study Coordination

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

SECONDARYHLAGACAC

Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

SECONDARYHLAGAKAA

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

• Clinical trial coordination
• Oncology research services
• Hematology clinical studies
• Disease registry services
• Sponsor representation trials

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Clinical Trial Sponsorship Services: AGMT acts as sponsor representative and contractual research organization for international clinical trials, coordinating with pharmaceutical companies, international study groups (GHSG, GELTAMO, DSMM, SAKK, INSERM), and academic institutions. Revenue derives from trial coordination fees, regulatory services, and grants from industry and institutional partners.
2. Grant Funding and Public Research Contracts: As a non-profit organization (gemeinnützige GmbH), AGMT receives grant funding from pharmaceutical industry partners, public research institutions, and international study groups for conducting investigator-initiated and industry-sponsored clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

AGMT is a non-profit Austrian academic clinical research organization (CRO) that conducts multicenter phase I–III clinical trials in oncology and hematology and serves as the Austrian sponsor representative for international trials sponsored by groups such as GHSG, GELTAMO, DSMM, GMMG, INSERM, SAKK, LYSARC, and GWT-TUD. It maintains multiple disease registries (aMYELOIDr, ARIADNE NIS, CLL-Register, EMCL-Registry, LungCA, MBC, mCRC-3L, NGS Register) that capture Austrian real-world treatment data, and organizes scientific events including the annual AGMT Jahresmeeting and Salzburg Breast Cancer Talk conference.

Product overview

AGMT (Arbeitsgemeinschaft medikamentöse Tumortherapie) is an Austrian non-profit clinical research organization comprising scientific clinicians and researchers in oncology, hematology, and related fields. Their portfolio consists of: (1) Clinical Trials spanning Hodgkin Lymphoma (HD21, BRESELIBET), Non-Hodgkin Lymphoma (DSHNHL_NIVEAU, Pola-R-ICE, R-Pola-Glo, MorningLyte), Multiple Myeloma (MM-4, DSMM XVII, GMMG-HD8, GMMG-HD9), Breast Cancer (MBC-10/CARIXA), Colorectal Cancer (SAKK 41/14 Active-2), Pancreatic Cancer (DIsCOvER), and COVID-19 (INSERM_DisCoVeRy); (2) Patient Registries including aMYELOIDr, CLL-Register, MBC Registry, LungCA Registry, and others for capturing real-world treatment data; (3) Scientific Events including the AGMT Jahresmeeting and Salzburg Breast Cancer Talk conference. The organization acts as sponsor representative in Austria for international trials and focuses on improving patient outcomes through clinical research.

Differentiator

Problem solved

Functional benefit

Products and services

• HD 21
• BRESELIBET
• DSHNHL_NIVEAU
• Pola-R-ICE
• R-Pola-Glo
• MorningLyte
• MM-4
• DSMM XVII
• GMMG-HD8 / DSMM XIX
• GMMG-HD9 / DSMM XVIII
• DIsCOvER
• INSERM_DisCoVeRy
• MBC-10 (CARIXA)
• Patient Registries
• AGMT Jahresmeeting (Annual Meeting)
• Salzburg Breast Cancer Talk

Quantifiable outcome

• 1585 international patients enrolled in HD21 Hodgkin Lymphoma trial
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core.

• GHSG — German Hodgkin Study GroupcoreStrategic or Co-development PartnerGHSG is the sponsor of the HD21 trial (advanced Hodgkin lymphoma), with AGMT serving as sponsor representative in Austria. AGMT coordinates Austrian participation in GHSG trials and contributes to the international Hodgkin lymphoma research network.
• GELTAMO — Grupo Español de Linfomas y Trasplante Autólogo de Médula ÓseacoreStrategic or Co-development PartnerGELTAMO is the sponsor of the BRESELIBET trial (relapsed/refractory classical Hodgkin's Lymphoma), with AGMT serving as sponsor representative in Austria. This partnership enables Austrian participation in this Spanish-led international salvage therapy trial.
• DSMM — Deutsche Studiengruppe Multiples MyelomcoreStrategic or Co-development PartnerDSMM cooperates with AGMT on multiple myeloma trials (DSMM_XVII, GMMG-HD8/DSMM XIX, GMMG-HD9/DSMM XVIII). AGMT serves as sponsor representative in Austria for trials conducted in cooperation with DSMM and the German-Speaking Myeloma Multicenter Group (GMMG).
• GMMG — German-Speaking Myeloma Multicenter GroupcoreStrategic or Co-development PartnerGMMG cooperates with AGMT on GMMG-HD8 and GMMG-HD9 trials. AGMT serves as sponsor representative in Austria. The partnership focuses on transplant-eligible and maintenance therapy in newly diagnosed multiple myeloma.
• INSERM — Institut national de la santé et de la recherche médicalecoreStrategic or Co-development PartnerINSERM is the sponsor of the DisCoVeRy trial (COVID-19 treatments in hospitalized adults), with AGMT as sponsor representative in Austria. This is an add-on trial to WHO SOLIDARITY, using the global randomization tool of SOLIDARITY.
• SAKK — Swiss Group for Clinical Cancer ResearchcoreStrategic or Co-development PartnerSAKK is the sponsor of the SAKK 41/14 Active-2 trial (physical activity in metastatic colorectal cancer), with AGMT as sponsor representative in Austria. This partnership brings Swiss-led cancer research to Austrian trial sites.
• GWT-TUD GmbHcoreStrategic or Co-development PartnerGWT-TUD GmbH is the sponsor of the Pola-R-ICE phase III trial (relapsed DLBCL), with AGMT as sponsor representative in Austria. Trial conducted in Germany, UK, Spain, and Austria.
• Klinische Krebsforschung IKF GmbHcoreStrategic or Co-development PartnerIKF GmbH is the sponsor of the R-Pola-Glo phase II trial (previously untreated aggressive B-cell lymphoma in elderly patients), with AGMT as sponsor representative in Austria.
• The Lymphoma Academic Research Organisation (LYSARC)coreStrategic or Co-development PartnerLYSARC is the sponsor of the MorningLyte phase III trial (follicular lymphoma), with AGMT as sponsor representative in Austria. LYSARC is the clinical research organization of the European Lymphoma Institute.
• University Hospital WürzburgcoreStrategic or Co-development PartnerUniversity Hospital Würzburg cooperates with DSMM on the DSMM_XVII trial (elotuzumab + carfilzomib in newly diagnosed multiple myeloma), with AGMT as sponsor representative in Austria.
• Ruprecht-Karls-Universität HeidelbergcoreStrategic or Co-development PartnerRuprecht-Karls-Universität Heidelberg cooperates with GMMG and DSMM on the GMMG-HD8/DSMM XIX trial (isatuximab in transplant-eligible NDMM), with AGMT as sponsor representative in Austria.
• Salzburg Cancer Research Institute (SCRI)coreStrategic or Co-development PartnerAGMT cooperates with SCRI (including LIMCR — Laboratory of Immunological and Molecular Cancer Research and CCCIT — Center for Clinical Cancer and Immunology Trials) on organizing the Salzburg Breast Cancer Talk conference and broader oncology research activities.
• Cancer Cluster Salzburg (CCS)coreStrategic or Co-development PartnerAGMT cooperates with Cancer Cluster Salzburg on the Salzburg Breast Cancer Talk conference series and broader immuno-oncology research networking in the Salzburg region.
• Paracelsus Medical University SalzburgcoreStrategic or Co-development PartnerAGMT collaborates with Paracelsus Medical University Salzburg, where key AGMT investigators (Prof. Richard Greil, Prof. Gabriel Rinnerthaler, Prof. Simon Gampenrieder) hold positions at the IIIrd Medical Department, University Hospital Salzburg.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• GMMG – German-Speaking Myeloma Multicenter Group: Germany's specialist cooperative group for multiple myeloma, partner on GMMG-HD8 and GMMG-HD9 trials with AGMT as Austrian sponsor representative. GMMG is the most direct multiple-myeloma peer — both organizations sponsor/coordinate transplant-eligible NDMM and maintenance therapy trials in the DACH region.
• IKF GmbH – Klinische Krebsforschung: German clinical cancer research organization and sponsor of the R-Pola-Glo phase II trial with AGMT as Austrian sponsor representative. IKF is a directly comparable small/mid-size academic CRO operating as a national sponsor representative in Germany for lymphoma and other oncology trials.
• SAKK – Swiss Group for Clinical Cancer Research: Switzerland's national cooperative oncology group conducting multicenter trials across all major tumor types. AGMT and SAKK have a documented partnership (SAKK 41/14 Active-2 colorectal trial with AGMT as Austrian sponsor representative), making SAKK the closest structural peer — both are national academic CROs operating in the DACH region for the same sponsor pool.
• CECOG – Central European Cooperative Oncology Group: Central European academic oncology cooperative covering Austria, CEE and SEE countries. CECOG is a regional peer with overlapping geographic scope (Austria) and a comparable mission of running multinational academic oncology trials in the region — making it a structural competitor for Austria-based trial mandates.
• LYSARC – The Lymphoma Academic Research Organisation: Clinical research organization of the European Lymphoma Institute, sponsor of the MorningLyte follicular lymphoma trial with AGMT as Austrian sponsor representative. LYSARC is the directly comparable peer for lymphoma-focused academic CRO activity in Europe.
• GELTAMO – Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea: Spain's national lymphoma cooperative group, sponsor of the BRESELIBET trial with AGMT as Austrian sponsor representative. GELTAMO is the structural twin of AGMT within Spain — both function as national AROs that anchor Austrian and Spanish trial sites, respectively, for lymphoma research.
• GHSG – German Hodgkin Study Group: Germany's specialist cooperative group for Hodgkin lymphoma, sponsor of the HD21 trial in which AGMT acts as Austrian sponsor representative. GHSG is the directly comparable peer on the trial-sponsor side for hematologic malignancy research in the DACH region.
• GWT-TUD GmbH: Dresden-based clinical research organization and sponsor of the Pola-R-ICE phase III trial with AGMT as Austrian sponsor representative. GWT-TUD is a directly comparable German academic CRO with the same operational model of acting as sponsor representative for international multicenter hematology trials.
• DSMM – Deutsche Studiengruppe Multiples Myelom: German multiple myeloma study group partnering with AGMT on DSMM XVII, GMMG-HD8/DSMM XIX, and GMMG-HD9/DSMM XVIII trials. DSMM operates the same DACH-region myeloma trial ecosystem as AGMT, and the two organizations collaborate rather than compete on shared sponsorships.

Broad incumbents

• EORTC – European Organisation for Research and Treatment of Cancer: Pan-European academic cancer research organization running multinational clinical trials across solid tumors and hematologic malignancies. EORTC is the broader incumbent peer — overlapping with AGMT on trial coordination but operating at continental scale rather than as a national sponsor representative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/agmt-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arbeitsgemeinschaft medikamentöse Tumortherapie